INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.

Veterinary Immunology and Immunopathology is a premier journal published by Elsevier, dedicated to advancing the field of veterinary science through rigorous investigations into the immunological mechanisms that underpin disease resistance, pathogenesis, and therapeutic interventions in animals. With an established history since 1979, this journal has consistently provided a platform for high-quality research, bridging the gap between immunology and veterinary medicine. The current impact factor reflects its significance within the field, particularly noted for its Q3 ranking in Immunology and Q2 in miscellaneous Veterinary categories as of 2023. The journal caters to a diverse audience, from seasoned researchers to students, by publishing original research, reviews, and case studies that explore pivotal topics such as vaccine development, immune response in various species, and the role of genetics in immunological disorders. Notably, it is indexed in Scopus, where it ranks in the top percentile of veterinary science disciplines, enhancing its visibility and impact within the scientific community. For those seeking to stay at the forefront of veterinary immunology, this journal is an invaluable resource.

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

NATURE IMMUNOLOGY is a premier academic journal published by NATURE PORTFOLIO, dedicated to advancing the field of immunology. With an impressive impact factor that reflects its esteemed position, this journal ranks in the top quartile (Q1) of renowned categories, including Immunology and Allergy. Serving as a crucial platform for researchers, professionals, and students, NATURE IMMUNOLOGY showcases cutting-edge research, comprehensive reviews, and insightful perspectives that drive innovation in immunological science. Based in the United Kingdom, this journal has been a vital contributor to the global discourse on immune responses and related diseases since its inception in 2000. Researchers can benefit from its rigorous peer-review process, ensuring that only high-quality studies are disseminated, thus enhancing their academic pursuits and practical applications. Explore the latest findings and trends within this flourishing discipline, making NATURE IMMUNOLOGY an essential resource for anyone engaged in the study of the immune system.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Immunotherapy, published by Future Medicine Ltd, is a leading journal focused on the evolving field of immunotherapy within the realms of immunology, oncology, and allergy. With an ISSN of 1750-743X and an E-ISSN of 1750-7448, this academic journal has been at the forefront of groundbreaking research since 2009, and continues to illuminating insights in a landscape critical for the development of innovative therapeutic strategies through 2024. Positioned within Q2 and Q3 quartiles in various relevant categories, the journal ranks commendably in Scopus metrics, exhibiting robust engagement and relevance in Oncology and Immunology. It serves as an essential resource for researchers, clinicians, and students eager to stay abreast of advancements in immunotherapy, while also providing an open platform for sharing impactful studies. By disseminating high-quality research, Immunotherapy fosters a global dialogue among professionals and contributes significantly to the scientific community's collective knowledge on the increasing role of immune-based therapies in disease management.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.